bioMérieux

Stocks

Market Closed - Euronext Paris Other stock markets 16:55:00 10/06/2026 BST			5-day change	1st Jan Change
70.15 ^EUR	-1.61%		-0.92%	-36.40%

06-09	What Bundibugyo Ebola vaccines and treatments are under development	RE
06-04	What Bundibugyo Ebola vaccines and treatments are under development	RE

Published on 04/23/2026 at 02:50 pm BST - Modified on 04/23/2026 at 04:40 pm BST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Welcome to the bioMérieux 2025 Third Quarter Sales Conference Call. The call will be structured in 2 parts. First, a presentation by bioMérieux Group

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

06-09	What Bundibugyo Ebola vaccines and treatments are under development	RE
06-04	What Bundibugyo Ebola vaccines and treatments are under development	RE
06-01	BioMérieux in the red following UBS downgrade
06-01	UBS Downgrades bioMérieux to Neutral, Cuts PT	MT
06-01	UBS downgrades bioMérieux to neutral, shares retreat
06-01	French Analyst Ratings: UBS downgrades Biomerieux, Soitec remains in favor
05-29	Biomérieux Invests EUR 250 Million to Build New Manufacturing Facility in France	CI
05-29	BioMérieux to build new production facility in Isère
05-29	BioMérieux to Spend EUR250 Million on New French Manufacturing Facility	MT
05-27	Minaris Advanced Therapies, LLC Expands Rapid Mycoplasma Detection Services With bioMérieux's BIOFIRE Platform To Reduce Turnaround Time For Release And In-Process Testing	CI
05-19	Test shortages slow fight against Ebola in Congo, WHO official says	RE
05-07	The Rally Spreads
05-06	L'Institut Merieux: bought an extra 1% in Biomérieux, bringing its total stake in company to around 60%	RE
04-24	Deutsche Bank Downgrades bioMérieux to Hold, Cuts PT	MT
04-23	BioMerieux: Disappointing Q1 and lower guidance undermine investor confidence